Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 83 of 116

  1. 2018-523-00US1

    Hutchmed Europe B.V.

    Lymphoma

    phase 1 other active

    1 trial

  2. 20180146

    Amgen

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 1 other active

    1 trial

  3. 20190135

    Amgen

    Advanced Solid Tumors Kirsten Rat Sarcoma (KRAS) pG12C Mutation

    phase 1 other active

    1 trial

  4. 2020-306-GLOB1

    Hutchmed Europe B.V.

    - Acute myeloid leukemia - Myelodysplastic syndrome/ Myeloproliferative neoplasm - Angio-immunoblastic T-cell lymphoma - Other mIDH-positive hematological malignancies (other than tumor types mentioned above)

    phase 1 other active

    1 trial

  5. 20200469

    Amgen

    Extensive Stage Small cell lung cancer (ES-SCLC)

    phase 1 other active

    1 trial

  6. 20220028

    Amgen

    Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

    phase 1 other active

    1 trial

  7. 20230167

    Amgen

    Thoracic tumors with homozygous MTAP-deletion

    phase 1 other active

    1 trial

  8. 20230223

    Amgen

    Gastrointestinal tract, biliary tract, or pancreatic cancers with homozygous methylthioadenosine phosphorylase (MTAP)-deletion

    phase 1 other active

    1 trial

  9. 20230237

    Amgen

    Newly diagnosed localized Intermediate or High‐Risk Prostate Cancer

    phase 1 other active

    1 trial

  10. 20230298

    Amgen

    Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

    phase 1 other active

    1 trial

  11. 20240031

    Amgen

    KRAS Altered Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  12. 20240124

    Amgen

    Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    phase 1 other active

    1 trial

  13. 20250004

    Amgen

    microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors

    phase 1 other active

    1 trial

  14. 20511

    Bayer AG

    Prostate cancer

    phase 1 other active

    1 trial

  15. 208850

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  16. 2138-CL-0101

    Astellas Pharma GmbH

    Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

  17. 217228

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  18. 21820

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  19. 21948

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  20. 22049

    Bayer Australia Ltd

    Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expression

    phase 1 other active

    1 trial

  21. 2223-001

    KYOWA KIRIN AUSTRALIA PTY LTD

    T-cell Non-Hodgkin Lymphoma, Cutaneous T-cell lymphoma (CTCL), Peripheral T-cell lymphoma (PTCL)

    phase 1 other active

    1 trial

  22. 22231

    Bayer AG

    Advanced solid tumors, Non-small cell lung cancer

    phase 1 other active

    1 trial

  23. 22262

    Bayer AG

    hepatocellular carcinoma (HCC)

    phase 1 other active

    1 trial

  24. 22676

    Bayer AG

    Advanced solid tumors harboring KRAS G12C mutation

    phase 1 other active

    1 trial

  25. 23U-0502

    Disc Medicine

    Metastatic colorectal cancer

    phase 1 other active

    1 trial

  26. 2X-121 and dovitinib

    Allarity Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule on hold

    1 trial

  27. 2mg INO-5150 and electroporation device CELLECTRA®-5P

    INOVIO PHARMACEUTICALS, INC.

    Prostate Cancer

    phase 1 mab completed

    1 trial

  28. 3-dimensional conformal radiation therapy

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 1 other active

    1 trial

  29. 300163

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  30. 4010-01-001

    TESARO Bio Netherlands B.V.

    Patients with Advanced Solid Tumors

    phase 1 other active

    1 trial

  31. 42756493BLC1003

    Janssen-Cilag International N.V.

    Localized Bladder Cancer

    phase 1 other active

    1 trial

  32. 609A

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Solid Tumors

    phase 1 small molecule active

    2 trials

  33. 64264681LYM1001

    Janssen-Cilag International N.V.

    non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  34. 64264681LYM1002

    Janssen-Cilag International N.V.

    non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  35. 64619178EDI1001

    Janssen-Cilag International N.V.

    Previously treated lymphoma (blood cancer) or solid tumors and NHL

    phase 1 other active

    1 trial

  36. 64Cu-DOTA-TLX592

    Telix Innovations

    Metastatic Prostate Cancer

    phase 1 small molecule completed

    1 trial

  37. 67652000PCR1001

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 1 other active

    1 trial

  38. 67856633LYM1001

    Janssen-Cilag International N.V.

    Non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  39. 67856633LYM1002

    Janssen-Cilag International N.V.

    Non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  40. 68-Ga PSMA11

    Telix Innovations

    Prostate Adenocarcinoma

    phase 1 small molecule active

    1 trial

  41. 68Ga-AAZTA-NI-093

    The First People's Hospital of Lianyungang

    Prostate Cancer (Adenocarcinoma)

    phase 1 small molecule active

    1 trial

  42. 68Ga-BNU-PSMA

    The First People's Hospital of Lianyungang

    Tumor

    phase 1 other active

    1 trial

  43. 68Ga-DOTA/NOTA-FAPI-04

    The First People's Hospital of Lianyungang

    Tumor

    phase 1 small molecule active

    1 trial

  44. 68Ga-FAPI-Biotin

    The First People's Hospital of Lianyungang

    Tumor

    phase 1 small molecule active

    1 trial

  45. 68Ga-JH04

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  46. 68Ga-JH12

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  47. 68Ga-MGS5

    The First People's Hospital of Lianyungang

    Medullary Thyroid Carcinoma

    phase 1 small molecule active

    1 trial

  48. 68Ga-NNS309

    Novartis Pharmaceuticals

    Pancreatic Ductal Adenocarcinoma

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.